Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres

Journal of Nuclear Medicine

Volumn 48, Issue 12, 2007, Pages 2080-2086

  Gulec, Seza A ^a   Siegel, Jeffry A ^a,b  

^a Goshen Health System   (United States)

^b Nuclear Physics Enterprises   (United States)

Author keywords

90Y; Microspheres; Radiation safety; Radiomicrosphere treatment; Selective internal radiation treatment

Indexed keywords

MICROSPHERE Y 90; TRACER; UNCLASSIFIED DRUG;

ARTICLE; BREAST MILK; GONAD; HUMAN; IN VIVO STUDY; LACTATION; MATHEMATICAL MODEL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION SAFETY;

BREAST FEEDING; FEMALE; FETUS; GONADS; HUMANS; MICROSPHERES; PREGNANCY; RADIATION DOSAGE; RADIATION PROTECTION; RADIOPHARMACEUTICALS; SAFETY; YTTRIUM RADIOISOTOPES;

EID: 36849008049     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.045443     Document Type: Article

References (26)

1. Ariel IM, Pack GT. Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy. Cancer. 1967;20:793-804.
2. Harbert JC, Robertson JS, Held KD. Nuclear Medicine Therapy. New York, NY: Thieme Medical Publishers; 1987:239-256.
3. Gray B, Van Hazel G, Hope M, et al. Randomized trial of SIR-spheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711-1720.
4. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3 - comprehensive literature review and future direction. J Vasc Interv Radiol. 2006;17:1571-1593.
5. Gulec SA, Fong Y. Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Arch Surg. 2007;142:675-682.
6. Sirtex Medical. SIR-Spheres (yttrium-90 microspheres) [package insert]. Available at: http://www.sirtex.com/. Accessed October 16, 2007.
7. Sirtex Medical. SIR-Spheres training program for physicians and institutions. Available at: http://www.sirtex.com/usa/_ _data/page/549/TRN-US- 0320for20US1.pdf. Accessed October 23, 2007.
8. MDS Nordion. TheraSphere (yttrium-90 glass microsphere) [package insert]. Available at: http://www.mdsnordion.com/. Accessed October 16, 2007.
9. U.S. Nuclear Regulatory Commission. 2007-10: Yttrium-90 Theraspheres and SirSpheres Impurities. Washington, DC: U.S. Nuclear Regulatory Commission; 2007. NRC Information Notice.
10. 2 glasses for the in vivo delivery of beta radiation. J Biomed Mater Res. 1993;27:1301-1308.
11. U.S. Nuclear Regulatory Commission. Criteria for the Release of Individuals Administered Radioactive Material. 10 CFR Parts 20 and 35: 62 FR 4120. Washington, DC: U.S. Nuclear Regulatory Commission; 1997.
12. U.S. Nuclear Regulatory Commission. Model Procedure for Release of Patients or Human Research Subjects Administered Radioactive Materials. NUREG-1556, Vol. 9, Rev. 1, Appendix U. Washington, DC: U.S. Nuclear Regulatory Commission; 2005:U-5.
13. Zanzonico PB, Binkert BL, Goldsmith SJ. Bremsstrahlung radiation exposure from pure β-ray emitters. J Nucl Med. 1999;40:1024-1028.
14. Siegel JA. Nuclear Regulatory Commission Regulation of Nuclear Medicine: Guide for Diagnostic Nuclear Medicine and Radiopharmaceutical Therapy. Reston, VA: Society of Nuclear Medicine; 2004.
15. Siegel JA, Marcus CS, Sparks RB. Calculating the absorbed dose to others from the radioactive patient: line source model versus point source model. J Nucl Med. 2002;43:1241-1244.
16. 131I- tositumomab therapy. J Nucl Med. 2002;43:354-363.
17. Wiseman GA, Leigh B, Witzig T, Gansen D, White C. Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma [abstract]. Eur J Nucl Med. 2001;28:1198.
18. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-873.
19. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
20. Hunt JG, Nosske D, dos Santos DS. Estimation of the dose to the nursing infant due to direct irradiation from activity present in maternal organs and tissues. Radiat Prot Dosimetry. 2005;113:290-299.
21. Stabin MG, Eckerman KF, Ryman JC, Williams LE. Bremsstrahlung radiation dose in yttrium-90 therapy applications. J Nucl Med. 1994;35:1377-1380.
22. Brent RL. Developmental and reproductive risks of radiological procedures utilizing ionizing radiation during pregnancy. In: Radiation Protection in Medicine: Contemporary Issues. Proceedings of the Thirty-Fifth Annual Meeting of the National Council on Radiation Protection and Measurements. Proceedings No. 21. Arlington, VA: National Council on Radiation Protection and Measurements; 1999:43-47.
23. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267-272.
24. Siegel JA. Quantitative bremsstrahlung SPECT imaging: attenuation-corrected activity determination. J Nucl Med. 1994;35:1213-1216.
25. Shen S, DeNardo GL, DeNardo SJ. Quantitative bremsstrahlung imaging of Y-90 using a Wiener filter. Med Phys. 1994;21:1409-1417.
26. Siegel JA, Zeiger LS, Order SE, Wallner PE. Quantitative bremsstrahlung SPECT imaging: use for volume, activity, and absorbed dose calculations. Int J Radiat Oncol Biol Phys. 1995;31:953-958.